WO2002090354A1 - Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides - Google Patents
Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides Download PDFInfo
- Publication number
- WO2002090354A1 WO2002090354A1 PCT/FR2002/001521 FR0201521W WO02090354A1 WO 2002090354 A1 WO2002090354 A1 WO 2002090354A1 FR 0201521 W FR0201521 W FR 0201521W WO 02090354 A1 WO02090354 A1 WO 02090354A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compounds
- phenyl
- aryl
- alkyl
- Prior art date
Links
- 0 CC(*)(C=C(CN)C=C1)C=C1OC Chemical compound CC(*)(C=C(CN)C=C1)C=C1OC 0.000 description 4
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N O=C/C=C/c1ccccc1 Chemical compound O=C/C=C/c1ccccc1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Definitions
- Novel derivatives of 1 azole or triazole, process for their preparation and their use as fungicides are Novel derivatives of 1 azole or triazole, process for their preparation and their use as fungicides.
- the present invention relates to new azole or triazole derivatives, their preparation process and their use as fungicides.
- the objective of the present invention is to provide new compounds having an antifungal activity, in particular with regard to the Candida or Aspergillus strains.
- a subject of the invention is the compounds of formula (I)
- X is a nitrogen atom or a CH group
- Ar 1 represents a carbocyclic or heterocyclic aryl which is unsubstituted or substituted by one or more radicals R 2 , R 3 or R 4
- Ar 2 represents a phenylene or naphthylene unsubstituted or substituted by one or more radicals R 5 , R 6 or R 7
- Ar 3 represents a carbocyclic or heterocyclic aryl unsubstituted or substituted by one or more radicals R 8 , R 9 or R 10
- A represents a (C 1 -C 4 ) -alkylene radical or a C (O) radical
- R 1 represents a hydrogen atom, a group -S0 3 H or a radical (C ⁇ -C 6 ) -alkyl unsubstituted or substituted by a radical as defined for R 2 R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 or R 10 identical or different, represent fluorine, chlorine, bromine, cyano, mono-bi- or trihalogeno (Ci-Ca) alkyl, mono-bi- or trihalogeno (Ci -Ce) - alkyloxy, hydroxy, nitro, carboxyl, formyl, -S0 3 H, -0S0 3 H, (R xl O) 2 P (0) -, (R xl 0) 2 P (0) -0-, amino, (Ci-Ce) - alkylamino, di ((C ⁇ -C 8 ) alkyl) amino, (C 5 -C14) -aryl
- R 11 represents hydrogen, (C1-C 10 ) -alkyl, (C 6 -C 1 4) -aryl or (C 6 -C ⁇ 4 ) -aryl- (C ⁇ -C 6 ) -alkyl, in all their stereoisomeric forms possible and their mixtures, as well as their physiologically acceptable addition salts and their prodrugs. All the radicals which can be found several times in the compounds of formula (I), for example, the radical R 2 , are independent of each other and can be identical or different.
- alkyl radicals mentioned above can be linear, branched or cyclic, saturated or mono- or polyunsaturated. This also applies when they have a substituent or when they are included in groups such as, for example, alkoxy, alkoxycarbonyl or aralkyl.
- (Ci-Ce) -saturated alkyl is meant methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl radicals, the n-isomers of these radicals, isopropyl, isobutyl, isopentyl, neopentyl, isohexyl, 3 -methylpentyl, 2, 3, 4-trimethylhexyl, sec-butyl, tert-butyl, tert-pentyl.
- (C ⁇ -C 6 ) -alkyl means methyl, ethyl, propyl, butyl, pentyl, hexyl and the n-isomers of these radicals.
- alkyloxy radical interrupted by one or more oxygen atoms is preferably meant radicals of the type 0-CH 2 -0- (CH 2 ) 2-0-CH 3 .
- Unsaturated alkyl radicals can contain one or more, for example one, two or three double and / or triple link.
- an unsaturated alkyl radical contains at least two carbon atoms.
- unsaturated alkyl radical is therefore meant, for example, alkenyl radicals such as vinyl, 1-propenyl, allyl, butenyl, 3-methyl-2-butenyl or alkynyl radicals such as ethynyl, 1-propynyl or propargyl.
- unsaturated bivalent alkylene radicals is meant the alkenylene and alkynylene radicals which can also be linear or branched. These are, for example, vinylene, propenylene, ethynylene or propynylene radicals.
- Cycloalkyl radicals can be monocyclic, bicyclic or tricyclic. These are, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyle, cycloundecyle, cyclododecyle, cyclotetradecyle or cyclooctadecyle which may, where appropriate, be substituted, for example, by an alkyl containing 1 to 4 atoms. carbon.
- substituted cycloalkyl radicals mention may be made of 4-methylcyclohexyl, 2,3-dimethylcyclohexyl, dimethylcyclopropane and dichlorocyclopropane.
- the alkyl or cycloalkyl radicals may be unsubstituted or substituted by one or more identical or different radicals chosen from (C ⁇ -C 6 ) -alkyl, (C ⁇ -C 6 ) -alkoxy, hydroxyl, halogen such as fluorine, chlorine and bromine, nitro, amino, trifluoromethyl, mono, -0CF 3 , cyano, carboxyl, -S0 3 H, -OS0 3 H, P0 3 H 2 / OP0 3 H 2 , (C 1 -C 4 ) - alkoxycarbonyl, phenyl, phenoxy, benzyl and benzyloxy.
- radicals chosen from (C ⁇ -C 6 ) -alkyl, (C ⁇ -C 6 ) -alkoxy, hydroxyl, halogen such as fluorine, chlorine and bromine, nitro, amino, trifluoromethyl, mono, -0CF 3 , cyano, carboxy
- alkyl radical is part of a group containing it, for example such as, (Ci-C ⁇ ) -alkyloxycarbonyle, (Ci-C ⁇ ) -alkylcarbonyle or (C ⁇ -C 6 ) -alkylaminocarbonyle
- Halogen means fluorine, chlorine, bromine or iodine.
- aryle means:
- the (C 6 -C ⁇ 4 ) -aryl carbocyclic radicals are - or the (C 6 -C ⁇ 4 ) -aryl carbocyclic radicals.
- the (C 6 -Ci) -aryl carbocyclic radicals mention may be made of phenyl, naphthyl, biphenylyl, anthryl or fluorenyl and very particularly 1-naphthyl, 2-naphthyl and phenyl.
- the aryl radicals, in particular phenyl may be unsubstituted or substituted by one or more identical or different radicals chosen from (C ⁇ -C 5 ) -alkyl, (C !
- -C 6 -alkoxy, hydroxyl, hydroxy (Ci-C ⁇ ) -alkyl, halogen such as fluorine, chlorine and bromine, nitro, amino, trifluoromethyl, -0CF 3 , cyano, carboxyl, -S0 3 H, -OS0 3 H, P0 3 H 2 , OP0 3 H 2 , (C ⁇ -C 4 ) -alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy and methylenedioxy.
- halogen such as fluorine, chlorine and bromine, nitro, amino, trifluoromethyl, -0CF 3 , cyano, carboxyl, -S0 3 H, -OS0 3 H, P0 3 H 2 , OP0 3 H 2 , (C ⁇ -C 4 ) -alkoxycarbonyl, phenyl, phenoxy, benzyl, benzyloxy and methylenedioxy
- the substituent can be located in position 2, 3 or 4, and preferably in position 3 or 4.
- Ar 3 represents a phenyl substituted in position 4.
- the substituents can be in position 2,3 or 2,4 or 2,5 or 2,6 or 3,4 or 3,5.
- Ar 1 represents a disubstituted phenyl
- the two substituents are in position 2,4.
- this phenyl is tri-substituted the positions are as follows: 2,3,4 or 2,3,5 or 2,3,6 or 2,4,5 or 2,4,6 or 3,4,5.
- naphthyl radicals or other aryl radicals can be substituted in any position, for example the 1-naphthyl radical in position 2-, 3-, 4-, 5-, 6-, 7-, and 8 and the 2-naphthyl radical in positions 1-, 3-, 4-, 5-, 6-, and 7.
- the (C 5 -C 14 ) -aryl group can also represent a monocyclic or polycyclic aromatic system in which 1,2,3 or 4 ring carbon atoms are replaced by heteroatoms, in particular identical or different from the group consisting of l , oxygen and sulfur.
- the heterocyclic system can be substituted by the same substituents mentioned above for the carbocyclic system.
- aryl is a radical included in a group such as aryl-alkyl.
- aryl-alkyl groups mention may be made of benzyl, 1-phenylethyl or 2-phenylethyl.
- heterocycle preferably means a 5 or 6-membered non-aromatic radical optionally containing one or two double bonds and one or more nitrogen or oxygen atoms substituted or unsubstituted by the same substituents mentioned above for the carbocyclic system as well as the oxo radical.
- the invention thus comprises the following heterocycles:
- the optically active carbon atoms contained in the compounds of formula (I) can independently of each other have the R configuration or the S configuration.
- the compounds of formula (I) may be in the form of pure enantiomers or pure diastereomers or as a mixture of enantiomers, for "example in the form of racemates or mixtures of diastereoisomers.
- the present invention therefore relates to pure enantiomers, mixtures of these enantiomers, pure diastereoisomers and mixtures of these diastereoisomers.
- the invention includes mixtures of two or more of two stereoisomers of formula (I) and all of the ratios of these stereoisomers within said mixtures.
- the compounds of formula (I) can optionally be present in the form of E isomers or Z isomers.
- the subject of the invention is therefore pure E isomers, pure Z isomers and E / Z mixtures in a ratio any.
- these compounds of formula (I) may be present in the form of cis or trans isomers.
- the subject of the invention is therefore pure cis isomers, pure trans isomers and cis / trans mixtures in any ratio.
- the invention also includes all the tautomeric forms of the compounds of formula (I).
- the diastereoisomers including the E / Z (or cis / trans) isomers can be separated into individual isomers, for example by chromatography.
- the racers can be separated into two enantiomers by standard methods such as chiral chromatography or by resolution methods.
- physiologically acceptable salts of the compounds of formula (I) are in particular pharmaceutically usable or non-toxic or physiologically usable salts.
- the compounds of formula (I) contain an acid group such as the carboxylic acid, they are, for example, alkali or alkaline earth metal salts such as the sodium, potassium, magnesium, calcium salts, and also the salts formed with physiologically acceptable quaternary ammonium ions and the addition salts with acids such as ammonia and physiologically acceptable organic amines such as for example triethylamine, ethanolamine or tris- ( 2-hydroxyethyl) amine.
- the compounds of formula (I) contain a basic group, they can form an addition salt with acids, for example with inorganic acids such as hydrochloric, sulfuric, phosphoric acid or with the om O LT) o LT) rH CM CN ro
- a subject of the invention is also the prodrugs of the compounds of formula (I) which can be transformed into compounds of formula (I) in vivo under physiological conditions.
- the prodrugs of the compounds of formula (I), namely the chemically modified derivatives of the compounds of formula (I) in order to obtain desired improved properties, are known to those skilled in the art.
- prodrugs of the compounds of formula (I) mention may preferably be made of: - the prodrugs in the form of esters of carboxylic, sulfonic or phosphonic groups, when, for example, Ar 3 is substituted respectively by a group -C0 2 H, -S0 3 H or -P0 3 H. the prodrugs in the form of acyl and carbamate for the groups containing an acylable nitrogen such as the amino or guanidine groups.
- prodrugs in the form of quaternary derivatives of cyclic nitrogen or not (substituted benzyl).
- acylated or carbamate prodrugs one or more times, for example twice, a hydrogen atom located on the nitrogen atom is replaced by an acyl or carbamate group.
- R ⁇ 2 CO-, R i3 OCO- in which R ⁇ 2 is hydrogen or a (C ⁇ -C ⁇ 8 ) -alkyl, (C 3 -C 14 ) - cycloalkyl, (C 3 -C ⁇ 4 ) -cycloalkyle- (C -C 8 ) -alkyle, (C 5 -C ⁇ 4 ) - aryl, in which 1 to 5 carbon atoms can be replaced by heteroatoms such as N, 0, S or (C 5 -C 14 ) - aryl- (C ⁇ -C 8 ) alkyl, in which 1 to 5 carbon atoms in the aryl part can be replaced by heteroatoms such as N, 0, S and R ⁇ 3 at the same values as R 12 with the exception of hydrogen.
- Ar 1 , Ar 2 , Ar 3 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 may adopt the above definitions independently of each other.
- Ar 1 and Ar 3 represent phenyl groups
- Ar 1 represents a phenyl group and Ar 3 represents a heterocycle
- A is preferably a methylene group
- R 1 is preferably a hydrogen atom or a methyl or ethyl group unsubstituted or substituted by fluorine, -OH, -NH 2 , (C ⁇ -C 8 ) -alkyloxy, (C ⁇ -C 8 ) -alkylamino, or di - (Ci-Ce) -alkylamino, pyrrolidino or 2-oxo-pyrrolidino.
- R 2 and R 3 are preferably halogen atoms
- R 4 is preferably a hydrogen atom
- R 6 is preferably a hydrogen atom
- R 5 and R 7 preferably represent hydrogen
- R 9 and R 10 preferably represent hydrogen, CN, halogen, -CF 3 , -0CF 3 , OH, -S0 3 H, -P (O) (OH) 2 , Carboxy, -OS0 3 H, -OP0 3 H, -NH 2 , (Ci-Ce) -alkyle, a heterocyclic radical saturated or unsaturated non aromatic, amino- (Ci-C ⁇ ) -alkyle, hydroxy- (C ⁇ _C 6 ) -alkyle, (C ⁇ -C 6 ) -alkyloxy, (C ⁇ -C 6 ) -alkylamino- (C ⁇ -C 6 ) - alkyloxy, (Ci-C ⁇ ) -alkyloxycarbonyle, (dC 6
- B, X, Ar, R and R are as defined above and R 2 and R 3 represent a chlorine or fluorine atom as well as their physiologically acceptable addition salts.
- a more particular subject of the invention is the compounds of formula (I) or (IA) as defined above in which R and R 3 are fluorine or chlorine atoms, X represents CH or N and Ar 3 represents a group phenyl unsubstituted or substituted by R 8 as defined above, as well as their physiologically acceptable addition salts.
- a very particular subject of the invention is the compounds of formula (I) or (IA) as defined above in which, R 1 is a hydrogen atom or a methyl or ethyl group, unsubstituted or substituted by a group F, OH, NH 2 , (C ⁇ -C 6 ) -alkyloxy, (C ⁇ -C 6 ) - alkylamino, di- (Ci-Ce) -alkylamino, pyrrolidino or 2-oxo-pyrrolidino as well as their physiologically acceptable addition salts.
- R 1 is a hydrogen atom or a methyl or ethyl group, unsubstituted or substituted by a group F, OH, NH 2 , (C ⁇ -C 6 ) -alkyloxy, (C ⁇ -C 6 ) - alkylamino, di- (Ci-Ce) -alkylamino, pyrrolidino or 2-oxo-pyrrol
- a very particular subject of the invention is the compounds of formula (IA) as defined above in which Ar 3 is a phenyl which is unsubstituted or substituted by R 8 representing a radical -Cl, -F, CN, -CF 3 , -0CF 3 , -OH, -NH 2 / (Ci-Ce) -alkyloxy, (C ⁇ -C 6 ) -alkylamino, di- (Ci-Ce) - alkylamino or a heterocycle chosen from:
- the invention particularly relates to the following compounds:
- the subject of the invention is also a process for preparing the compounds of formula (I) characterized in that a compound of formula (II) is subjected:
- This reaction is carried out under the conventional nucleophilic substitution conditions of the R-OH + R'-OTs -> R-O-R 'type known to those skilled in the art, Ts being a Tosyle group.
- the base used can in particular be sodium hydride and the solvent can be DMF.
- the compound of formula (II) is reacted with an aryl of formula (III ') HO-C 4 H 6 -CHO in the presence of a base, the phenyl being unsubstituted or substituted by R 5 , in order to obtain a compound of formula (IIa)
- OHC-CH CH-C 6 H 4 -R 8 or OHC- (Cyclopropyl) -C 6 H 4 -R 8 followed by a reduction reaction in the presence of a reducing agent such as NaBH 3 CN or pyridine.
- a reducing agent such as NaBH 3 CN or pyridine.
- the first reductive amination reaction involving the aldehyde (11a) is preferably carried out in the presence of reagents such as NaBH 3 CN in methanol or pyridin.BH 3 .
- the second reductive amination reaction involving the amine (Ile) with a trans cinnamaldehyde derivative is also preferably carried out in the presence of NaBH 3 CN in methanol.
- the reaction involving the amine (Ile) with an allyl acetate is carried out in the presence of a palladium derivative, for example in acetonitrile / water medium (tppts / Pd (OAc) 2 ) •
- the compound of formula (IIa) is reacted with an amine of formula R ' 1 - (CH 2 ) 2 -NH 2 , R' 1 representing a group F, OH, an amine or an alkylamine which being suitably protected (such as NHC0 2 tbu, pyrrolidino, 2-oxo-pyrrolidino), or a dialkylamine in order to obtain a compound of formula (Ile), in the presence of a reducing agent such as NaBH 3 CN:
- the starting compounds of formula (II) or (III) can be prepared according to methods described in the literature or are accessible by analogy.
- the preparation of the compounds of formula (II) is described in Eur. J. Med. Che. (1995) 30, 617-626 or J. Heterocyclic Chemistry (1990), 27 2053, it being understood that the present invention is not limited to these syntheses or to these starting materials. There is no major difficulty for those skilled in the art to provide for modifications to the syntheses described in our application for the preparation of other compounds of formula (I) according to the invention.
- the compounds of formula (I) are compounds having a pharmacological activity and can thus be used as medicaments in particular as antifungal agents
- the subject of the present invention therefore is the compounds of formula (I) and / or their physiologically acceptable salts and / or their prodrugs as medicine.
- the compounds of formula (I) as well as their physiologically acceptable salts and their prodrugs can be administered to animals, preferably to mammals and in particular to humans as medicaments for therapeutic or prophylactic purposes.
- the compounds of formula (I) have interesting antifungal properties. They are particularly active on Candida albicans and other Candidas such as Candida glabrata, krusei, tropicalis, pseudotropicalis and parapsilosis, on Aspergillus, Aspergillus flavus, Aspergillus niger, Cryptococcus additionoformans, Mi crosporum cani s, Tri chophyton rubrun, Tri chophyton men tagry.
- the compounds of formula (I) can be used as a medicament in humans or animals, in particular for combating digestive, urinary, vaginal or skin candidiasis, cryptococcosis, for example neuromeningeal, pulmonary or skin cryptococcosis, bronchopulmonary and pulmonary aspergillosis and invasive aspergillosis of the immunocompromised.
- the compounds according to the invention can also be used in the prevention of fungal diseases in congenital or acquired immune depressed.
- the compounds of the invention are not limited to pharmaceutical use. They can also be used as fungicides in fields other than pharmaceuticals.
- the subject of the invention is therefore, as antifungal medicaments, the compounds of formula (I).
- a pharmacophore group having a fungicidal activity for example an azole or triazole derivative as defined above, for the preparation of medicaments exhibiting antifungal activity.
- the compounds according to the invention can be administered as such or in admixture with one or more other compounds of formula (I) or also in the form of a pharmaceutical preparation (pharmaceutical composition) which allows enteral or parenteral administration and which contains as active compound an effective dose of at least one compound of formula (I) and / or its physiologically acceptable salts and / or its prodrugs as well as common and pharmaceutically inert carriers and / or additives.
- a pharmaceutical preparation pharmaceutical composition
- compositions according to the invention allow enteral or parenteral administration which contain, as active compound, an effective dose of at least one compound of formula (I) and / or its physiologically acceptable salts and / or its prodrugs as well as a or more pharmaceutically inert carriers, and / or one or several usual additives.
- a subject of the invention is therefore pharmaceutical compositions containing a compound of formula (I) as defined above as well as a vehicle.
- the drugs can be administered orally, for example, as a pill, tablet, coated tablet, film, granule, soft capsule or capsule, solution, syrup, emulsion, suspension, or mixture of aerosol. Administration can however be carried out rectally, for example in the form of a suppository, by parenteral route, for example in the form of injectable solutions or infusions, of microcapsules or implants, by percutaneous route, for example in the form ointment, solutions, pigments or dyes, transdermally in the form of patches or by other routes such as in the form of aerosol or nasal spray.
- compositions according to the invention are prepared according to methods known per se, pharmaceutically inert organic or inorganic supports being added to the compounds of formula (I) and / or their physiologically acceptable salts and / or their prodrugs.
- pharmaceutically inert organic or inorganic supports being added to the compounds of formula (I) and / or their physiologically acceptable salts and / or their prodrugs.
- suitable supports for soft gelatin capsules or for suppositories are for example fats, waxes, semi-solid or liquid polyols, natural or modified oils etc.
- the vehicles suitable for the preparation of solutions are for example water, alcohols, glycerol, polyols, sucrose, invert sugars, glucose, vegetable oils, etc.
- Suitable supports for microcapsules or implants are, for example, copolymers of glyoxilic acid and lactic acid.
- Pharmaceutical preparations - normally contain 0.5% to 90% by weight of compounds of formula (I) in • H CQ 1 CQ T3
- the daily dose generally varies from 0.01 to 100 mg / kg and preferably from 0.1 to 50 mg / kg, in particular from 0.1 to 5 mg / kg.
- the daily dose varies approximately from 0.01 to 100 mg / kg and preferably from 0.05 to 10 mg / kg.
- the daily dose can be divided, in particular in the case of the administration of large amount of active ingredient, into several, for example 2,3 or 4 parts. If necessary, depending on individual behavior, it may be necessary to administer the different doses in an increasing or decreasing manner.
- the compounds of formula (I) and their salts can also be used as intermediates for the preparation of other compounds, in particular other active agents, which are accessible from the compounds of formula (I), for example by modification or introduction of radicals or functional groups.
- DMSO dimethyl sulfoxide; Pd / C Palladium on carbon; Boc terbutoxycarbonyl; CBz: benzyloxycarbonyl; DCC 1,3-dicyclohexylcarbodiimide; IR: Infrared; NMR: Nuclear Magnetic Resonance; SM: Mass spectrum; ESP: Electrospray positive mode; ep. : Shoulder; F: strong; s: singlet; d: doublet; t: triplet; quad: quadruplet; quint: quintuplet; 1: wide; m: multiplet or massive; J: coupling constant; Rf: retention factor (chromatography).
- the NMR spectra below have been interpreted and the aromatic hydrogens are thus identified
- 4-hydroxy-1-naphthalenecarboxaldehyde (860 mg, 5 mmol) to 260 mg of 55% sodium hydride in vaseline oil in 20 cm3 of DMF, then 2.41 g of [Cis- [2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-yl] methyl 4-methyl-benzenesulfonate and stir 6 hours at 60 ° C then 12 hours at room temperature.
- reaction medium is poured onto ice water, extracted with dichloromethane, washed with 2N sodium hydroxide solution then with a saturated NaCl solution, dried, filtered and then evaporated under reduced pressure until a crude product is obtained which purified by recrystallization from cyclohexane. 1.58 g of expected product are obtained.
- ethylamine hydrochloride (1.33 g, 20 immoles) then sodium cyanoborohydride (124 mg, 2 mmol) and stirred for 12 hours at room temperature.
- Example 1 cis-4- [[2- (2,4-dichlorophenyl) -2- (1H-imidazol-1- yl ethyl) -1, 3-dioxolan-4-yl] methoxy] -N-methyl-N - (3-phenyl- 2 (E) -propenyl) -benzenemethanamine
- Example 2 cis-4- [[2- (2,4-dichlorophenyl) -2- (1H-imidazol-1- ylmethyl) -1, 3-dioxolan-4-yl] methoxy] -N- (3-phenyl -2 (E) - propenyl) -4- ⁇ hloro-benzenememethanamine
- TPPTS sodium salt of tris (3-sulfonatophenyl) phosphine tetrahydrate, STREM CHEMICAL
- P3_ amino derivative of tris (3-sulfonatophenyl) phosphine tetrahydrate
- P3_ amino derivative of tris (3-sulfonatophenyl) phosphine tetrahydrate
- P3_ amino derivative of tris (3-sulfonatophenyl) phosphine tetrahydrate
- E para-chloro- (E) -cinnamyl acetate
- Example 6 cis-4- [[2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-yl] methoxy] -N-methyl-N- (3-phenyl- 2 (E) -propenyl) -1-naphthalenemethanamine
- Example 9 cis-N- (2-aminoethyl) -N- [3- (4-chlorophenyl) -2 (E) - propenyl] -4- [[2- (2,4-dichlorophenyl) -2- (1H -imidazol-1- ylmethyl) -1,3-dioxolan-4-yl] methoxy] -benzenemethanamine
- N-CH 2 -Cq N-CH 2 -Cq
- Example 10 cis-2- [[[4- [[2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-yl] methoxy] phenylJmethyl] (3-phenyl-2 (E) -propenyl) amino] -ethanol
- Excipient q.s.p. 1 g Details of the excipient: starch, talc, magnesium stearate.
- mice Female mice weighing 18-22 g are used. They are administered a quantity of Candida albicans 44858 in the tail vein at the rate of 10 6 CFU per mouse (CFU: colony-forming unit). The mice are separated into 5 batches of 5 mice and they are treated as follows: One hour after the infection group 1: the mice are treated with the product P 25 mg / kg orally group 2: the mice are treated with product P intraperitoneally at a rate of 25 mg / kg - group 3: the mice are treated with fluconazole (25 mg / kg orally). group 4: the mice are treated with fluconazole (25 mg / kg intraperitoneally). group 5: the mice do not receive any antifungal treatment.
- CFU colony-forming unit
- Candida albicans cells are prepared as indicated in the Journal of Antimicrobial chemotherapy 38,
- the MICs are determined by the modification of a microtiter plate according to the standard method of the National Committee for clinical laboratory standards.
- RPMI-1640 is used as medium, and L-glutamine buffered to pH7 with a 0.15 M solution of MOPS (3- [N- morpholino] sulfonic propane).
- MOPS 3- [N- morpholino] sulfonic propane.
- Candida albicans cells (1.5 X 10 3 cells / ml) are added to the wells of a 96-well plate containing RPMI-1640 and the dilutions of antifungal agents. The results are read 48 hours after incubation at 35 ° C. and the MIC or minimum inhibitory concentration which inhibits the growth of Candida albicans cells is determined.
- Minimum fungicide concentration 1.5 X 10 3 cells / ml
- the plates are shaken and 10 ⁇ L of aliquot are removed from the wells which are placed on rectangular disks containing dextrose agar. The plates are incubated for 48 hours at 35 ° C; The minimum fungicidal concentration and the concentration of the antifungal agent at which the number of colony forming units is zero.
- the compounds according to the invention described in examples 1 to 10 have an activity of ⁇ 100 ⁇ g / ml in the MIC test.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002587433A JP4434589B2 (ja) | 2001-05-04 | 2002-05-02 | 新規なアゾールまたはトリアゾール誘導体、それらの製造方法およびそれらの殺菌剤としての使用 |
DE60209708T DE60209708T2 (de) | 2001-05-04 | 2002-05-02 | Azol- oder triazol-derivate, verfahren zu deren herstellung und ihre verwendung als fungizide |
US10/477,112 US6946460B2 (en) | 2001-05-04 | 2002-05-02 | Azole or triazole derivatives, method for preparing same and use thereof as fungicides |
EP02730384A EP1387841B1 (fr) | 2001-05-04 | 2002-05-02 | Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/05958 | 2001-05-04 | ||
FR0105958A FR2824325B1 (fr) | 2001-05-04 | 2001-05-04 | Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002090354A1 true WO2002090354A1 (fr) | 2002-11-14 |
Family
ID=8862966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/001521 WO2002090354A1 (fr) | 2001-05-04 | 2002-05-02 | Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides |
Country Status (10)
Country | Link |
---|---|
US (1) | US6946460B2 (fr) |
EP (1) | EP1387841B1 (fr) |
JP (1) | JP4434589B2 (fr) |
AT (1) | ATE319708T1 (fr) |
DE (1) | DE60209708T2 (fr) |
DK (1) | DK1387841T3 (fr) |
ES (1) | ES2258625T3 (fr) |
FR (1) | FR2824325B1 (fr) |
PT (1) | PT1387841E (fr) |
WO (1) | WO2002090354A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012177986A2 (fr) | 2011-06-22 | 2012-12-27 | Vyome Biosciences | Promédicaments antifongiques et antibactériens à base d'un conjugué |
WO2014195872A1 (fr) | 2013-06-04 | 2014-12-11 | Vyome Biosciences Pvt. Ltd. | Particules enrobées et compositions les comprenant |
EP3698793A1 (fr) | 2014-01-29 | 2020-08-26 | Vyome Therapeutics Limited | Bésifloxacine pour traiter l'acné résistante |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5958905B2 (ja) * | 2011-10-20 | 2016-08-02 | 公立大学法人秋田県立大学 | 植物成長調節剤 |
CN111387185A (zh) * | 2020-05-08 | 2020-07-10 | 兰州大学 | 一种萘替芬类似物在防治农业植物病害中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0050298A2 (fr) * | 1980-10-16 | 1982-04-28 | Hoechst Aktiengesellschaft | 1-(1,3-dioxolan-2-ylméthyl)-azoles, procédé pour leur préparation et leur application |
EP0121753A2 (fr) * | 1983-03-10 | 1984-10-17 | Hoechst Aktiengesellschaft | 1-(1,3-Dioxolan-2-ylméthyl)-azoles, leur sels, leurs procédés de préparation et les préparations pharmaceutiques les contenant |
WO2000020413A1 (fr) * | 1998-10-06 | 2000-04-13 | Aventis Pharma S.A. | Nouveaux derives de la 2-[3-phenyl-2-propenyl]-1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides |
WO2001074808A1 (fr) * | 2000-04-05 | 2001-10-11 | Aventis Pharma S.A. | Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides |
-
2001
- 2001-05-04 FR FR0105958A patent/FR2824325B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-02 DK DK02730384T patent/DK1387841T3/da active
- 2002-05-02 ES ES02730384T patent/ES2258625T3/es not_active Expired - Lifetime
- 2002-05-02 US US10/477,112 patent/US6946460B2/en not_active Expired - Fee Related
- 2002-05-02 EP EP02730384A patent/EP1387841B1/fr not_active Expired - Lifetime
- 2002-05-02 PT PT02730384T patent/PT1387841E/pt unknown
- 2002-05-02 WO PCT/FR2002/001521 patent/WO2002090354A1/fr active IP Right Grant
- 2002-05-02 AT AT02730384T patent/ATE319708T1/de active
- 2002-05-02 JP JP2002587433A patent/JP4434589B2/ja not_active Expired - Fee Related
- 2002-05-02 DE DE60209708T patent/DE60209708T2/de not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0050298A2 (fr) * | 1980-10-16 | 1982-04-28 | Hoechst Aktiengesellschaft | 1-(1,3-dioxolan-2-ylméthyl)-azoles, procédé pour leur préparation et leur application |
EP0121753A2 (fr) * | 1983-03-10 | 1984-10-17 | Hoechst Aktiengesellschaft | 1-(1,3-Dioxolan-2-ylméthyl)-azoles, leur sels, leurs procédés de préparation et les préparations pharmaceutiques les contenant |
WO2000020413A1 (fr) * | 1998-10-06 | 2000-04-13 | Aventis Pharma S.A. | Nouveaux derives de la 2-[3-phenyl-2-propenyl]-1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides |
WO2001074808A1 (fr) * | 2000-04-05 | 2001-10-11 | Aventis Pharma S.A. | Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012177986A2 (fr) | 2011-06-22 | 2012-12-27 | Vyome Biosciences | Promédicaments antifongiques et antibactériens à base d'un conjugué |
WO2014195872A1 (fr) | 2013-06-04 | 2014-12-11 | Vyome Biosciences Pvt. Ltd. | Particules enrobées et compositions les comprenant |
EP3698793A1 (fr) | 2014-01-29 | 2020-08-26 | Vyome Therapeutics Limited | Bésifloxacine pour traiter l'acné résistante |
Also Published As
Publication number | Publication date |
---|---|
JP4434589B2 (ja) | 2010-03-17 |
US6946460B2 (en) | 2005-09-20 |
DK1387841T3 (da) | 2006-07-03 |
DE60209708T2 (de) | 2006-09-21 |
PT1387841E (pt) | 2006-06-30 |
FR2824325B1 (fr) | 2003-08-15 |
JP2004529942A (ja) | 2004-09-30 |
EP1387841B1 (fr) | 2006-03-08 |
EP1387841A1 (fr) | 2004-02-11 |
ATE319708T1 (de) | 2006-03-15 |
DE60209708D1 (de) | 2006-05-04 |
US20050043540A1 (en) | 2005-02-24 |
FR2824325A1 (fr) | 2002-11-08 |
ES2258625T3 (es) | 2006-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2321323B9 (fr) | Derives dimeriques d'artemisinine et application en therapie anticancereuse | |
EP3164393B1 (fr) | Dérivés de flavaglines | |
LU85826A1 (fr) | Alpha-aminoacides substitues,leur fabrication et compositions pharmaceutiques les contenant | |
WO2002090354A1 (fr) | Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides | |
EP2331555B1 (fr) | Dérives ferroceniques a activite anticancereuse | |
EP1257552B1 (fr) | Derives de xanthine, intermediaires et application au traitement de l'osteoporose | |
EP0318392B1 (fr) | Nouveaux dérivés N-(vinblastinoyl-23) d'acide amino-1 méthylphosphonique, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
EP1387837B1 (fr) | Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme medicaments anti-fongiques | |
FI105270B (fi) | Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi | |
EP1272485A1 (fr) | Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides | |
EP1409461B1 (fr) | Nouveaux derives d'azole ou de triazole, leur procede de preparation et leur application comme fongicides | |
EP0992502B1 (fr) | Nouveaux dérivés de la 2-/3-phényl-2-propényl/-1,2,3,4-tétrahydro-isoquinoléine, leur procédé de préparation et leur application comme fongicides | |
FR2582305A1 (fr) | Nouveaux composes azoliques, leur preparation et leur utilisation comme antifongiques et fongicides | |
EP0384812A1 (fr) | Trifluorométhoxy-5 benzimidazolamine-2, procédé pour sa préparation et médicaments la contenant | |
FR2793796A1 (fr) | Nouveaux derives d'imidazoles, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant | |
FR2706464A1 (fr) | Nouveaux dérivés de spirodiaza ou spirooxaaza alkylcyclotriphosphazènes substitués par des méthyl ou diméthyl aziridines, leur préparation et leur utilisation en tant que médicament. | |
LU86001A1 (fr) | Nouveau compose azolique,sa preparation et son utilisation comme antifongique et fongicide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ OM PH PL RO SG SI SK TN TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002730384 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002587433 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002730384 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10477112 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002730384 Country of ref document: EP |